Pharmacology data are scarce; in vitro transporter assays of related α-PVP analogs suggest nanomolar NET/DAT inhibition. A 2022 forensic case reported fatal ventricular tachycardia with femoral blood 26 ng/mL, illustrating low LD50 margin. Fluorine substitution is predicted to raise metabolic stability, extending active phase relative to alkyl-only peers. User reports indicate very rapid onset when freebased (steam on foil), but subjective potency roughly half that of α-PVP: common 'one-hit' loads are 10-15 mg, with compulsive re-hits every 10-15 min. Intranasal use burns intensely and produces drip-induced gagging; many switch to glass-pipe inhalation.
Also known as: MFPVP, 4f-3m-α-pvp, 4f-3me-α-pvp, 3-m-4-f-α-pvp, 3-methyl-4f-pvp, 4-fluoro-3-methyl-α-pyrrolidinopentiophenone
Classification
Chemical: Cathinone
Psychoactive: Stimulant
Tag: Pyrrolidine
Tag: Pyrrolidinophenone
Tag: Research-Chemical
Tag: Synthetic cathinone
Effects
Stimulation
Increased Heart Rate
Vasoconstriction
Increased Perspiration
Teeth Grinding
Sweating And Vasoconstriction
Euphoria
Compulsive Redosing
Anxiety
Paranoia
Focus Enhancement
Motivation Enhancement
Tactile Enhancement
Increased Libido
Light Sensitivity
Appetite Suppression
Disinhibition
Dehydration
Routes of Administration
Oral / Sublingual
Dosage
Threshold: 5 mg
Light: 5-15 mg
Common: 15-30 mg
Strong: 30-45 mg
Heavy: 45 mg
Duration
Onset: 0.25-0.5 h
Peak: 0.5-1.5 h
Offset: 1-2 h
After Effects: 2-6 h
Insufflated
Dosage
Threshold: 5 mg
Light: 5-20 mg
Common: 20-40 mg
Strong: 40-60 mg
Heavy: 60+ mg
Duration
Onset: 0.08-0.17 h
Peak: 0.5-1.5 h
Offset: 1-2 h
After Effects: 2-6 h
Total Duration: 2-3 h
Vaporized / Smoked (Freebase Foil / Mesh)
Dosage
Threshold: 3 mg
Light: 3-10 mg
Common: 10-15 mg
Strong: 15-20 mg
Heavy: 20 mg
Duration
Onset: 0.01 h
Peak: 0.03-0.17 h
Offset: 0.5-0.75 h
After Effects: 2-6 h
Oral
Dosage
Heavy: 45+ mg
Light: 5–15 mg
Common: 15–30 mg
Strong: 30–45 mg
Threshold: 5 mg
Duration
Onset: 0.25-0.5 h
Peak: 0.5-1.5 h
Offset: 2-3.5 h
After Effects: 3.5-9.5 h
Total Duration: 3-5 h
Sublingual
Dosage
Heavy: 45+ mg
Light: 5–15 mg
Common: 15–30 mg
Strong: 30–45 mg
Threshold: 5 mg
Duration
No data available for this section yet.
Smoked
Dosage
Heavy: 20+ mg
Light: 3–10 mg
Common: 10–15 mg
Strong: 15–20 mg
Threshold: 3 mg
Duration
Onset: 0.008-0.05 h
Peak: 0.03-0.17 h
Offset: 0.5-0.75 h
After Effects: 1-7 h
Total Duration: 1-1.5 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
4F-3-methyl-alpha-pvp - DrugsPRO vodič o supstancama
4F-3-methyl-alpha-pvp: Pharmacology data are scarce; in vitro transporter assays of related α-PVP analogs suggest nanomolar NET/DAT inhibition. A 2022 forensic case reported fatal ventricular tachycardia with femoral blood 26 ng/mL, illustrating low LD50 margin. Fluorine substitution is predicted to
